NAT10 and pachyonychia congenita: Further analysis revealed that NAT10 inhibition, in combination with PD-L1 blockade, exhibited a synergistic antitumor effect, offering a promising therapeutic strategy to overcome the immunosuppressive tumor microenvironment (TME) in PC(Fig. 9G).